メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
感染症学講座
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(5)
プロジェクト
(9)
研究成果
(258)
データセット
(11)
フィンガープリント
感染症学講座が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Acute Respiratory Tract Infection
18%
Adult Case
11%
Adult Patients
13%
Airway Epithelial Cells
15%
Amphotericin B
21%
Ampicillin Resistance
13%
Antibiotics
20%
Aspergillus Fumigatus
14%
Azithromycin
21%
Bacteremia
21%
Bacterial Infection
11%
Bacterial Pneumonia
22%
Biapenem
14%
Bronchoalveolar Lavage Fluid
14%
Calcineurin
11%
Candida
11%
Candida Glabrata
19%
Candidemia
18%
Carbapenems
12%
Chemotherapy
13%
Chest CT
18%
Clarithromycin
22%
Clinical Characteristics
27%
Clinical Efficacy
25%
Clinical Features
12%
Clinical Specimens
11%
Combination Therapy
17%
Community-acquired Pneumonia
30%
COVID-19
62%
Cryptococcosis
12%
Cryptococcus
11%
Cryptococcus Neoformans
25%
Cystic Fibrosis
13%
Daptomycin
24%
Fever
16%
Fluconazole
19%
Fluoroquinolones
14%
Fusobacterium nucleatum (F. nucleatum)
11%
Garenoxacin
11%
Haemophilus Influenzae
24%
Healthcare-associated Pneumonia
11%
Hematogenous
19%
High Dose
12%
Hospitalized Patients
15%
Immunocompromised Patients
13%
In Vivo Efficacy
29%
Infectious Diseases
13%
Influenza Pneumonia
17%
Influenza Virus
17%
Invasive Pulmonary Aspergillosis
12%
Itraconazole
14%
Japan
100%
Levofloxacin
18%
Linezolid
57%
Lung
47%
Macrolides
12%
Meropenem
12%
Methicillin-resistant Staphylococcus Aureus
68%
Micafungin
17%
Minimum Inhibitory Concentration
17%
Mouse Model
23%
Mucin 5AC (MUC5AC)
19%
Murine Model
41%
Mycobacterium Tuberculosis (M. tb)
16%
Nagasaki
37%
Neoformans
19%
Neutralizing Antibodies
12%
Neutrophils
11%
Older Men
18%
Patients with COVID-19
13%
Pharmacokinetics
20%
Piperacillin
14%
Pneumonia
40%
Population Pharmacokinetics
11%
Pseudomonas Aeruginosa (P. aeruginosa)
38%
Pulmonary Cryptococcosis
39%
Pulmonary Infection
21%
Quantitative PCR
25%
Rapid Detection
12%
Resistant Strains
11%
Respiratory Infection
28%
Rifampicin
16%
S. Pneumoniae
25%
Severe Pneumonia
11%
Sivelestat
11%
Sputum
13%
Staphylococcus Aureus
12%
Staphylococcus Aureus Bacteremia
16%
Streptococcus Pneumoniae
48%
Survival Rate
11%
Therapeutic Drug Monitoring
16%
Thrombocytopenia
24%
Underlying Disease
12%
University Hospital
16%
Vancomycin
27%
Ventilator-associated Pneumonia
11%
Viable Bacteria
12%
Viral Load
16%
Virulence
12%
β-lactamase
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Agar
8%
Amphotericin B
23%
Ampicillin
8%
Antibiotics
15%
Antifungal Agent
13%
Antiinfective Agent
23%
Aspergillus
13%
Aspergillus fumigatus
12%
Azithromycin
13%
Bacterial Pneumonia
19%
Biapenem
12%
Bloodstream Infection
17%
Candida
10%
Carbapenem
9%
Ciprofloxacin
7%
Clarithromycin
18%
Clinical Feature
11%
Clinical Study
8%
Clinical Trial
9%
Coagulase
7%
Coccidioidomycosis
7%
Cohort Study
13%
Combination Therapy
17%
Community Acquired Pneumonia
26%
Coronavirinae
15%
Creatinine
6%
Cytokine
10%
Daptomycin
23%
Disease
25%
Disease Severity
9%
Erythromycin
9%
Fatality
6%
Favipiravir
6%
Fluconazole
9%
Flucytosine
7%
Fusobacterium nucleatum
8%
Garenoxacin
7%
Gatifloxacin
8%
Haemophilus influenzae
15%
Health Care Associated Pneumonia
12%
Hemodialysis
10%
Infection
75%
Infectious Agent
13%
Inflammation
9%
Interferon Type I
7%
Interleukin 6
9%
Invasive Aspergillosis
14%
Itraconazole
13%
Legionella
11%
Legionella pneumophila
13%
Legionnaire Disease
7%
Levofloxacin
18%
Linezolid
57%
Lipopolysaccharide
9%
Lung Abscess
11%
Lung Aspergillosis
14%
Lung Disease
7%
Lung Infection
17%
Macrolide
15%
Meropenem
12%
Methicillin Resistant Staphylococcus Aureus Infection
32%
Methicillin-Resistant Staphylococcus Aureus
62%
Micafungin
13%
Minimum Inhibitory Concentration
8%
Mortality Rate
10%
Mouse Model
18%
Mucin 5AC
15%
Mycobacterium Avium Complex
7%
Mycosis
11%
Neutralizing Antibody
9%
Panton-Valentine Leukocidin
6%
Pazufloxacin
10%
Penicillinase
12%
Pharmacodynamics
13%
Pharmacokinetics
41%
Piperacillin
10%
Piperacillin Plus Tazobactam
9%
Prevotella intermedia
7%
Pseudomonas aeruginosa
35%
Pulmonary Cryptococcosis
10%
Quinolone Derivative
19%
Randomized Controlled Trial
8%
Respiratory Failure
8%
Respiratory Tract Infection
37%
Rifampicin
9%
SARS Coronavirus
36%
Sepsis
8%
Sitafloxacin
10%
Sivelestat
11%
Staphylococcus Aureus
12%
Streptococcus
15%
Streptococcus Pneumonia
10%
Sultamicillin
9%
Survival Rate
7%
Teicoplanin
8%
Therapeutic Drug Monitoring
15%
Thrombocytopenia
24%
Vancomycin
23%
Ventilator Associated Pneumonia
7%
Medicine and Dentistry
Abscess
7%
Amphotericin B
12%
Ampicillin
5%
Ampicillin/Sulbactam
5%
Antibiogram
5%
Antibiotics
13%
Antifungal Agent
5%
Antiinfective Agent
17%
Aspergillus
7%
Bacterial Pneumonia
12%
Biapenem
5%
Blood Culture
9%
Bloodstream Infection
18%
Bronchoalveolar Lavage Fluid
5%
Chemotherapy
15%
Chest Radiograph
8%
Clinical Feature
8%
Clinical Study
5%
Clinical Trial
9%
Cohort Effect
5%
Cohort Study
8%
Community-Acquired Pneumonia
18%
Computer Assisted Tomography
17%
Coughing
9%
COVID-19
38%
Cryptococcosis
5%
Cystic Fibrosis
8%
Decision Making
5%
Differential Diagnosis
7%
Disease
15%
Drug Megadose
5%
Empyema
7%
Endocarditis
7%
Erysipelothrix rhusiopathiae
7%
Fulminant
7%
Fusobacterium nucleatum
6%
Gram Staining
6%
Ground Glass Opacity
7%
Haemophilus influenzae
8%
Health Care Associated Pneumonia
8%
High Fever
5%
Human Immunodeficiency Virus
7%
Infection
53%
Influenza Virus
7%
Interleukin 6
7%
Invasive Aspergillosis
11%
Itraconazole
7%
Klebsiella pneumoniae
6%
Legionella pneumophila
8%
Lung
21%
Lung Abscess
9%
Lung Aspergillosis
7%
Lung Transplantation
7%
Magnetic Resonance Imaging
5%
Meropenem
8%
Methicillin Resistant Staphylococcus Aureus
12%
Methicillin Resistant Staphylococcus Aureus Infection
6%
Micafungin
9%
Mixed Infection
6%
Nocardiosis
5%
Pathogen
22%
Pathogenicity
6%
Penicillinase
9%
Piperacillin
5%
Piperacillin/Tazobactam
7%
Pneumococcal Infection
9%
Pneumococcal Pneumonia
8%
Pneumococcus
22%
Prevotella intermedia
5%
Pseudomonas aeruginosa
13%
Pulmonary Cryptococcosis
11%
Respiratory Failure
10%
Respiratory Tract Infection
22%
Reverse Transcription Polymerase Chain Reaction
8%
Serotype
8%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Silo-Filler's Disease
9%
Sputum
18%
Streptococcus Pneumonia
9%
Thrombocyte Activating Factor Receptor
5%
Tuberculosis
5%
Vancomycin
7%